Amicus®
Mononuclear Cell (MNC) Collection

Precision Collection.
Soft, Safe Care.
Putting precision collections at your fingertips

Deliver high collection efficiencies

Meeting the patients’ clinical needs is always your primary goal. Our Gentle Science design delivers precision collections with the high efficiency required in clinical settings.

<table>
<thead>
<tr>
<th></th>
<th>Median, N=91</th>
<th>Median, N=17</th>
<th>Mean ± SD, 63.7 ± 14.9, n=12</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mobilized Patient¹</td>
<td>81%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MNC CE1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mobilized Donor¹</td>
<td>70%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MNC CE1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Non-mobilized donor², ‡</td>
<td>69%</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CD34+ CE1</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Providing soft, safe care to patients and donors

**Tailor collections**

Every MNC collection is different because every patient and donor is different. Amicus is designed to make it easy to tailor collections for high product purity and high MNC yield.

Longer MNC harvest can be achieved by increasing the RBC Offset to fully capture the MNCs.

<table>
<thead>
<tr>
<th>MNC CE1 (%)</th>
<th>Mobilized Patient±</th>
<th>Mobilized Donor±</th>
<th>Non-Mobilized Donor2</th>
<th>Median</th>
<th>n</th>
<th>Median</th>
<th>n</th>
<th>Median</th>
<th>n</th>
</tr>
</thead>
<tbody>
<tr>
<td>Platelets (x1011)</td>
<td>80</td>
<td>87</td>
<td>70</td>
<td>17</td>
<td>NR†</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematocrit (%)</td>
<td>0.43</td>
<td>96</td>
<td>0.57</td>
<td>18</td>
<td>0.46 ± 0.15</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product Volume (mL)</td>
<td>13.6</td>
<td>62</td>
<td>3.8</td>
<td>14</td>
<td>9.6 ± 2.6</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product Volume (mL)</td>
<td>176</td>
<td>97</td>
<td>160</td>
<td>18</td>
<td>50.4 ± 3.5</td>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

†MNC sub-populations were measured for this study. Mean CD34+ CE(%) was 63.7 ±14.9 (±SD).

±Mobilization with G-CSF + chemotherapy for patients and G-CSF alone for healthy subjects per institutional practice.

**Platelet sparing, for your patient and the product**

One therapeutic procedure shouldn’t result in the need for another. Our Gentle Science design allows you to perform MNC collections on patients with low platelet counts, with reduced risk for post collection platelet transfusions.3, 4

**Patient and donor comfort**

Comfort is a key part of the care you provide. With low extracorporeal volume (ECV) and quiet operation, Amicus delivers a gentle experience—even for fragile patients or donors.

Additionally, our kits are sterilized using irradiation to avoid the risk of residual ethylene oxide related reactions.

10% Median patient platelet loss1

191 mL Optia MNC6
163 mL Amicus5
285 mL Spectra7
References

5. Fresenius Kabi Operators Manual Fenwal Amicus MNC
7. COBE Spectra® Apheresis System • Essentials Guide

‡ Amicus is cleared for MNC collection. Further analysis was performed on collected MNC products using multiparameter flow cytometry; results may vary depending on analysis method.

Refer to the Amicus Separator Operator's Manual for the full list of warnings and cautions associated with the use of the device.

Trademarks referred to are property of their respective owners.